Optibiotix Health

About:

Optibiotix Health discovers and develops microbial strains, compounds and formulations, which modulate the human microbiome.

Website: http://www.optibiotix.com/

Twitter/X: optibiotix

Top Investors: Graham Myers

Description:

OptiBiotix develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

Total Funding Amount:

2.85M GBP

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Heslington, York, United Kingdom

Founded Date:

2006-07-19

Contact Email:

optibiotix(AT)walbrookpr.com

Founders:

Stephen O' Hara

Number of Employees:

11-50

Last Funding Date:

2024-03-25

IPO Status:

Public

Industries:

© 2025 bioDAO.ai